This highlighted study looks at using these 2 therapies concurrently for this infection.
Tiffany Lee, PharmD, BCIDP
Advertisement
Articles by Tiffany Lee, PharmD, BCIDP
Interests have recently skewed toward the use of carbapenem-sparing regimens in light of growing selection for carbapenem-resistant organisms.
Bezlotoxumab, a human monoclonal anti­body directed against Clostridioides diffi­cile toxin B, is currently indicated for the prevention of recurrent C diffi­cile infection
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
mRNA-based Influenza Vaccine Advances Against HHS Resistance
2
Review of Cefepime and Zidebactam: A Novel Antibiotic Approved to Treat Complicated Urinary Tract Infections
3
FDA Expands Merck Pneumococcal Vaccine Indication to Include At-Risk Children and Adolescents
4
Vaccine for Lassa Fever Succeeds in First-in-Human Trial
5